NCT00636792View on ClinicalTrials.gov

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Follicular Lymphoma
Interventions
DRUG

VELCADE

VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.

DRUG

Bendamustine

Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle

DRUG

Rituximab

Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5

Trial Locations (2)

20057

Georgetown University Medical Center, Washington D.C.

58501

MidDakota Clinic - Cancer Treatment and Research Center, Bismarck

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00636792 - A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma | Biotech Hunter | Biotech Hunter